How to buy mdma, this is the second of a two-part extract from the chapter on MDMA in Transform’s recently published book ‘How to Regulate Stimulants: A Practical Guide’ You can read Part 1 here, or buy a print copy of the book, or download a free pdf version, here.
While mis-selling of other drugs as MDMA pills have tailed off in recent years (although a problem that could return as 2021 data from the loop suggests), what might have been a positive development in some respects (greater certainty for consumers of the substance they are purchasing and a reduction in more risky adulterants and mis-spelling) has been countered by the growing risks from high potency MDMA pills and powder. The EMCDDA Trendspotter notes that ‘over
half (53 %) of all ecstasy tablets tested in 2015 [by the Netherlands Drug Information and Monitoring System (DIMS) that tests over 10,000 pills annually] contained over 140 milligrams of MDMA compared to just 3% in 2009.’ By 2018, an even greater 72% of samples contained over 150 milligrams of MDMA, with an average of 171 milligrams per pill — considerably higher than the average of 50-80 milligrams consistently seen in Europe across the 1990s and 2000s, and a steady rise from 2014. Recent years have also seen the rise of ‘super pills’- with a range of 270–340 milligrams — up to four times a normal adult dose. Rival producers, flush with low-cost raw materials, are competing with each other to market the strongest pills (even if, beyond a certain point, it is unclear whether this is something consumers actually want). The widening potential range of MDMA content in pills, combined with the emergence of super-high-strength pills has been identified as a key driver in the rapid rise in MDMA-related medical emergencies and deaths since 2013.